Compare CABA & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | PLBY |
|---|---|---|
| Founded | 2017 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 232.8M |
| IPO Year | 2019 | N/A |
| Metric | CABA | PLBY |
|---|---|---|
| Price | $2.39 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $13.50 | $3.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $119,510,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $8.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $0.90 |
| 52 Week High | $3.67 | $2.53 |
| Indicator | CABA | PLBY |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 49.81 |
| Support Level | $2.32 | $1.72 |
| Resistance Level | $2.48 | $1.97 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 17.50 | 14.81 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.